Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health (NASDAQ:COSM) projects its new nutraceutical Fort18™ will generate over $3.2 million in incremental annual U.S. revenue within 12–18 months, based on current commercialization plans and internal assumptions.

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) projects its new nutraceutical Fort18™ will generate over $3.2 million in incremental annual U.S. revenue within 12–18 months, based on current commercialization plans and internal assumptions.

Fort18™, targeting men's sexual stamina and endurance, is expected to launch in June 2026 via a staged rollout starting with e-commerce.

Positive

• Projects over $3.2 million in incremental annual U.S. revenue from Fort18™ within 12–18 months
• Fort18™> expands the 18 Series portfolio into the U.S. men's sexual health supplement category
• Staged rollout strategy starting with direct-to-consumer e-commerce and planned retail expansion

Negative

• None.

Argus May 11 session

-7.64% close to close Open Argus

Details

News Market Reaction – COSM

In the May 11 session, COSM declined 7.64%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.6% in the session following this news. A negative reaction despite positive reven...

Analysis

The stock moved -7.6% in the session following this news. A negative reaction despite positive revenue projections fits prior instances where upbeat announcements, such as the 18 Series launch on Apr 21 (next-day move -9.1%), were followed by selling. The stock traded about 46% below its 200-day MA before this release, and volume ran at only 0.33× its 20-day average. Recent capital structure disclosures, including registration of 73,523,716 shares for resale, also framed risk perceptions.

Key Figures

Fort18 projected revenue: over $3.2 million Projection timeframe: 12–18 months Launch timing: June 2026 +5 more

Fort18 projected revenue

over $3.2 million

Incremental annual U.S. revenue within 12–18 months

Projection timeframe

12–18 months

Fort18 incremental annual U.S. revenue outlook

Launch timing

June 2026

Expected U.S. commercial launch of Fort18

Global market size 2023

$3.52 billion

Global sexual health supplement market (Grand View Research)

Global market 2030 forecast

$7.02 billion

Projected global sexual health supplement market by 2030

CAGR

10.4%

Global sexual health supplement market growth 2023–2030

U.S. market size 2023

$965.8 million

U.S. sexual health supplement market (Grand View Horizon)

U.S. market 2030 forecast

$1.93 billion

Projected U.S. sexual health supplement market by 2030

Previous Crypto Reports

5 past events · Latest: May 06

Same Type 5 events

1. May 06

   Fort18 U.S. launch

   24h Move

   -0.8%

   Announced U.S. launch of Fort18 with positive clinical and dosing details.

2. Apr 30

   Cur18 revenue outlook

   24h Move

   +2.5%

   Projected over $2.5M in Cur18 annual U.S. revenue within 12–18 months.

3. Apr 17

   Cur18 U.S. launch plan

   24h Move

   +0.1%

   Outlined Q2 Cur18 U.S. launch with enhanced bioavailability data.

4. Apr 13

   Pharmalink order ramp

   24h Move

   +8.5%

   Reported third Sky Premium Life order, cumulative 270,000 units toward 3M goal.

5. Apr 10

   Record revenue update

   24h Move

   +3.5%

   Disclosed record Q3 2025 revenue and NOOR collagen U.S. growth plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nutraceutical, cagr

2 terms

nutraceutical medical

"a growing portfolio of science-based nutraceutical products."

A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.

cagr financial

"to $7.02 billion by 2030, growing at a CAGR of 10.4%."

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18^™ to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.

Fort18^™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products. Formulated with a proprietary botanical blend evaluated in published clinical research, Fort18^™ enters the U.S. sexual health supplement category targeting men's sexual stamina and endurance. The product is expected to launch commercially in June 2026.

The Company's projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company's commercialization plans.

According to Grand View Research, the global sexual health supplement market was valued at $3.52 billion in 2023 and is projected to nearly double to $7.02 billion by 2030, growing at a CAGR of 10.4%. The United States stands as one of the largest individual markets globally, estimated at $965.8 million in 2023 and forecast to reach $1.93 billion by 2030, according to Grand View Horizon.

Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "Fort18^™ marks our entry into the U.S. men's wellness category - a large and rapidly growing market driven by increasing consumer demand for science-supported products. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life^®, Mediterranation^®, bio-bebe^®, C-Sept^® and C-Scrub^®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

No statement made herein has been evaluated by the U.S. Food and Drug Administration. Any product described above is not intended to diagnose, treat, cure, or prevent any disease.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue does Cosmos Health (NASDAQ:COSM) project from Fort18™ in the U.S.?

Cosmos Health projects Fort18™ will generate over $3.2 million in incremental annual U.S. revenue within 12–18 months. According to Cosmos Health, this forecast is based on its current commercialization strategy and internal assumptions about pricing, volumes, repeat purchases, and distribution growth.

When will Cosmos Health launch Fort18™ in the United States?

Fort18™ is expected to launch commercially in the U.S. in June 2026. According to Cosmos Health, the product will begin with a direct-to-consumer e-commerce rollout, with plans to expand into selected retail channels over time as distribution scales.

What market segment does Fort18™ target for Cosmos Health (COSM)?

Fort18™ targets the U.S. men's sexual health supplement category, focusing on sexual stamina and endurance. According to Cosmos Health, it is the latest product in the science-based “18 Series” nutraceutical portfolio and marks entry into the U.S. men's wellness space.

How large is the sexual health supplement market relevant to Cosmos Health's Fort18™?

The global sexual health supplement market was valued at $3.52 billion in 2023, projected to reach $7.02 billion by 2030. According to Grand View Research, the U.S. market was $965.8 million in 2023 and is forecast to reach $1.93 billion by 2030.

What commercialization strategy is Cosmos Health using for Fort18™ in the U.S.?

Cosmos Health plans a staged rollout for Fort18™, starting with direct-to-consumer e-commerce. According to Cosmos Health, the forecasted revenue assumes planned expansion into selected retail channels and factors in pricing, expected sales volumes, repeat purchasing, and distribution growth.

Why does Cosmos Health believe Fort18™ can be a meaningful revenue contributor?

Cosmos Health believes Fort18™ can become a meaningful revenue contributor due to its positioning in a large, growing men's wellness market. According to Cosmos Health, the product uses a proprietary botanical blend evaluated in published clinical research and benefits from scalable distribution plans.